Line 116: |
Line 116: |
| '''Antibiotics''': if a pancreatic infection is suspected then [[Potentiated-Sulphonamides|trimethoprim-sulphonamide]] and [[Fluoroquinolones|enrofloxacin]] have good penetration to the pancreas. | | '''Antibiotics''': if a pancreatic infection is suspected then [[Potentiated-Sulphonamides|trimethoprim-sulphonamide]] and [[Fluoroquinolones|enrofloxacin]] have good penetration to the pancreas. |
| | | |
− | '''Analgesia''': should be given even without signs of pain. Recommended options include: subcutaneous pethidine, intravenous or continuous rate infusion morphine or transdermal fentanyl. Dogs can also be given intraperitoneal lidocaine or bupivacaine. | + | '''Analgesia''': should be given even without signs of pain. Recommended options include: subcutaneous [[Opioids#Pethidine|pethidine]], intravenous or continuous rate infusion [[Opioids#Morphine|morphine]] or transdermal [[Opioids#Fentanyl|fentanyl]]. Dogs can also be given intraperitoneal [[Local Anaesthetics#Lidocaine|lidocaine]] or [[Local Anaesthetics#Bupivicaine|bupivicaine]]. |
| | | |
− | '''Transfusion''': Plasma or whole blood can be given with severe disease to replace α-macroglobulins. Albumin also provides oncotic support and limits pancreatic ischaemia and oedema. | + | '''Transfusion''': [[Plasma - WikiBlood|Plasma]] or whole blood can be given with severe disease to replace α-macroglobulins. Albumin also provides oncotic support and limits pancreatic ischaemia and oedema. |
| | | |
− | '''Corticosteroids''':for short term use in fulminating pancreatitis to be given alongside fluids. Long term treatment may lead to unwanted complications. | + | '''[[Steroids|Corticosteroids]]''':for short term use in fulminating pancreatitis to be given alongside fluids. Long term treatment may lead to unwanted complications. |
| | | |
− | '''Dopamine''': helps reduce feline pancreatitis at doses of 5µg/kg/min i.v. | + | '''[[Dopamine]]''': helps reduce feline pancreatitis. |
| | | |
| '''Secretion prevention''': Has been found to have limited clinical use but high intravenous doses of secretin has been beneficial in rat models of pancreatitis. | | '''Secretion prevention''': Has been found to have limited clinical use but high intravenous doses of secretin has been beneficial in rat models of pancreatitis. |
Line 133: |
Line 133: |
| | | |
| '''Supportive care''': | | '''Supportive care''': |
− | Mild cases may only require 1 or 2 days of supportive treatment. Aggressive fluid therapy will be needed to treat dehydration and fluid loss from diarrhoea and vomiting. Monitoring of renal function and potassium levels which may need supplementing. Patients may also have metabiolic acidosis in acute pancreatitis or be alkalotic due to vomiting. Should diabetes mellitus develop, this may require treatment with insulin. Further management may be required for respiratory distress, bleeding disorders, renal failure, cardiovascular problems and neurological disorders although these all carry a poor prognosis. | + | Mild cases may only require 1 or 2 days of supportive treatment. Aggressive [[Fluid Therapy|fluid therapy]] will be needed to treat dehydration and fluid loss from [[Intestine Diarrhoea - Pathology|diarrhoea]] and [[Control of Feeding - Anatomy & Physiology#The Vomit Reflex|vomiting]]. Monitoring of renal function and potassium levels which may need supplementing. Patients may also have metabolic acidosis in acute pancreatitis or be alkalotic due to [[Control of Feeding - Anatomy & Physiology#The Vomit Reflex|vomiting]]. Should [[Diabetes mellitus - WikiClinical|diabetes mellitus]] develop, this may require treatment with insulin. Further management may be required for respiratory distress, bleeding disorders, renal failure, cardiovascular problems and neurological disorders although these all carry a poor prognosis. |
| | | |
| ===Long-term treatment=== | | ===Long-term treatment=== |